array:20 [
  "pii" => "XX886658107088599"
  "issn" => "X8866581"
  "estado" => "S300"
  "fechaPublicacion" => "2007-04-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Apunts. Medicina de l'Esport. 2007;42:88-91"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 3330
    "formatos" => array:3 [
      "EPUB" => 157
      "HTML" => 2011
      "PDF" => 1162
    ]
  ]
  "Traduccion" => array:2 [
    "en" => array:16 [
      "pii" => "13108884"
      "issn" => "18866581"
      "estado" => "S300"
      "fechaPublicacion" => "2007-04-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Apunts. Medicina de l'Esport. 2007;42:88-91"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:2 [
        "total" => 1477
        "formatos" => array:3 [
          "EPUB" => 146
          "HTML" => 1261
          "PDF" => 70
        ]
      ]
      "en" => array:7 [
        "idiomaDefecto" => true
        "titulo" => "Clinical utility of condroitin sulfate"
        "tieneTextoCompleto" => 0
        "tieneResumen" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "88"
            "paginaFinal" => "91"
          ]
        ]
        "contieneResumen" => array:1 [
          "en" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Josep Vergés"
            "autores" => array:1 [
              0 => array:2 [
                "nombre" => "Josep"
                "apellidos" => "Vergés"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "ct" => array:8 [
          "pii" => "XX886658107088599"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "ct"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088599?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13108884?idApp=UINPBA00004N"
      "url" => "/18866581/0000004200000154/v0_201801081334/13108884/v0_201801081334/en/main.assets"
    ]
    "es" => array:16 [
      "pii" => "X0213371707088843"
      "issn" => "02133717"
      "estado" => "S300"
      "fechaPublicacion" => "2007-04-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Apunts. Medicina de l'Esport. 2007;42:88-91"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:2 [
        "total" => 3220
        "formatos" => array:3 [
          "EPUB" => 137
          "HTML" => 2029
          "PDF" => 1054
        ]
      ]
      "es" => array:11 [
        "idiomaDefecto" => true
        "titulo" => "Utilidad clínica del condroitín sulfato"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "88"
            "paginaFinal" => "91"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Clinical utility of condroitin sulfate"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Josep Vergés"
            "autores" => array:1 [
              0 => array:2 [
                "nombre" => "Josep"
                "apellidos" => "Vergés"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "ct" => array:8 [
          "pii" => "XX886658107088599"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "ct"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088599?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0213371707088843?idApp=UINPBA00004N"
      "url" => "/02133717/0000004200000154/v0_201801081434/X0213371707088843/v0_201801081434/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:16 [
    "pii" => "XX886658107088603"
    "issn" => "X8866581"
    "estado" => "S300"
    "fechaPublicacion" => "2007-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Apunts. Medicina de l'Esport. 2007;42:92-8"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 3463
      "formatos" => array:3 [
        "EPUB" => 164
        "HTML" => 2235
        "PDF" => 1064
      ]
    ]
    "ct" => array:11 [
      "idiomaDefecto" => true
      "titulo" => "Esport i massa òssia (II). Característiques de l'exercici físic que condicionen el modelatge i el remodelatge ossis"
      "tienePdf" => "ct"
      "tieneTextoCompleto" => "ct"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "92"
          "paginaFinal" => "98"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Sports activity and bone mas (II). The characteristics of physical activity that affect bone formation and remodeling"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "ct" => true
      ]
      "contienePdf" => array:1 [
        "ct" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Caritat Bagur Calafat"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Caritat"
              "apellidos" => "Bagur Calafat"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "ct"
    "Traduccion" => array:2 [
      "en" => array:8 [
        "pii" => "13108885"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13108885?idApp=UINPBA00004N"
      ]
      "es" => array:8 [
        "pii" => "X0213371707088851"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0213371707088851?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088603?idApp=UINPBA00004N"
    "url" => "/X8866581/0000004200000154/v0_201801081416/XX886658107088603/v0_201801081416/ct/main.assets"
  ]
  "itemAnterior" => array:16 [
    "pii" => "XX886658107088580"
    "issn" => "X8866581"
    "estado" => "S300"
    "fechaPublicacion" => "2007-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Apunts. Medicina de l'Esport. 2007;42:82-7"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 3654
      "formatos" => array:3 [
        "EPUB" => 136
        "HTML" => 2360
        "PDF" => 1158
      ]
    ]
    "ct" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Valoració de la força útil en tennis"
      "tienePdf" => "ct"
      "tieneTextoCompleto" => "ct"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "82"
          "paginaFinal" => "87"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Evaluation of useful force in tennis"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "ct" => true
      ]
      "contienePdf" => array:1 [
        "ct" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "278v42n154-13108858fig01.jpg"
              "Alto" => 524
              "Ancho" => 700
              "Tamanyo" => 102348
            ]
          ]
          "descripcion" => array:1 [
            "ct" => "Cop de dreta en el tennis."
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Raúl Pablo Garrido Chamorro, Cristina Blasco Lafarga, Alejandro Ricardo Albert Giménez, Emilio José Poveda Pagán, Jesús Mas Martínez"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Raúl Pablo"
              "apellidos" => "Garrido Chamorro"
            ]
            1 => array:2 [
              "nombre" => "Cristina"
              "apellidos" => "Blasco Lafarga"
            ]
            2 => array:2 [
              "nombre" => "Alejandro Ricardo"
              "apellidos" => "Albert Giménez"
            ]
            3 => array:2 [
              "nombre" => "Emilio José"
              "apellidos" => "Poveda Pagán"
            ]
            4 => array:2 [
              "nombre" => "Jesús"
              "apellidos" => "Mas Martínez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "ct"
    "Traduccion" => array:2 [
      "en" => array:8 [
        "pii" => "13108883"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13108883?idApp=UINPBA00004N"
      ]
      "es" => array:8 [
        "pii" => "X0213371707088835"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0213371707088835?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088580?idApp=UINPBA00004N"
    "url" => "/X8866581/0000004200000154/v0_201801081416/XX886658107088580/v0_201801081416/ct/main.assets"
  ]
  "ct" => array:14 [
    "idiomaDefecto" => true
    "titulo" => "Utilitat clínica de la condroïtina sulfat"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "88"
        "paginaFinal" => "91"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Josep Vergés"
        "autores" => array:1 [
          0 => array:3 [
            "nombre" => "Josep"
            "apellidos" => "Vergés"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:3 [
            "entidad" => "Facultad de Medicina&#46; Universidad Aut&#243;noma de Madrid&#46; Madrid&#46; Espanya&#46;"
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Clinical utility of condroitin sulfate"
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold"> Introducci&#243;</span></p><p class="elsevierStylePara">La condro&#239;tina sulfat &#40;CS&#41; pertany al grup dels f&#224;rmacs d&#39;acci&#243; simptom&#224;tica lenta &#40;SYSADOA&#44; <span class="elsevierStyleItalic">symptomatic slow acting drug for osteoarthritis</span>&#41; caracteritzats perqu&#232; presenten una efic&#224;cia sobre els s&#237;mptomes semblant a la dels antiinflamatoris no estero&#239;dals &#40;AINE&#41; que comen&#231;a d&#39;una manera gradual per&#242; que es perllonga durant m&#233;s temps&#44; fins i tot despr&#233;s de la supressi&#243; del tractament &#40;efecte persistent o <span class="elsevierStyleItalic">carry over</span>&#41;&#46; Igualment&#44; es tracta de productes d&#39;una gran seguretat&#46;</p><p class="elsevierStylePara">Els assajos cl&#237;nics en pacients artr&#242;sics demostren que el tractament amb CS produeix una disminuci&#243; o desaparici&#243; dels s&#237;mptomes de la malaltia artr&#242;sica&#44; com s&#243;n el dolor i la impot&#232;ncia funcional&#44; i millora el moviment de les articulacions afectades&#44; amb un efecte que perdura 2 o 3 mesos&#46;</p><p class="elsevierStylePara">Com que es tracta d&#39;un f&#224;rmac d&#39;acci&#243; simptom&#224;tica lenta &#40;SYSADOA&#41;&#44; l&#39;inici d&#39;acci&#243; de la CS &#233;s una mica lent&#44; entre 2-3 setmanes&#44; per b&#233; que eventualment aconsegueix la mateixa efic&#224;cia que els antiinflamatoris&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Material i m&#232;todes</span></p><p class="elsevierStylePara">Per determinar l&#39;efic&#224;cia de la CS en el tractament simptom&#224;tic de l&#39;artrosi&#44; s&#39;han fet diversos assajos cl&#237;nics que posen de manifest la seva utilitat arran d&#39;aquesta afecci&#243;&#46; Tot seguit es resumeixen les evid&#232;ncies cl&#237;niques disponibles amb CS&#46;</p><p class="elsevierStylePara">S&#39;ha fet un assaig cl&#237;nic aleatoritzat&#44; multic&#232;ntric&#44; a doble cec&#44; amb 146 pacients amb artrosi del genoll i de 6 mesos de durada&#44; comparant el diclofenac s&#242;dic &#40;DS&#41; pres durant 30 dies respecte de la CS presa durant 90 dies<span class="elsevierStyleSup">1</span>&#46; Els resultats estan resumits en la figura 1&#46;</p><p class="elsevierStylePara"><img src="278v42n154-13108859tab01.gif"></img></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Figura 1</span> Efecte anti&#224;lgic i funcional del diclofenac s&#242;dic&#44; 150 mg&#47;dia durant 30 dies&#44; i de la condro&#239;tina sulfat &#40;CS&#41; 1&#46;200 mg durant 90 dies&#44; mesurats als 30&#44; 45&#44; 60 i 90 dies&#46; &#42;p &#60; 0&#44;05 respecte del diclofenac&#46;</p><p class="elsevierStylePara">Tenint en compte &#250;nicament les mesures de dolor i funcionals als 30 dies de tractament&#44; es pot concloure que la CS fa minvar el dolor espontani amb la mateixa efic&#224;cia que el DS&#46; Per&#242; als 30 dies de tractament&#44; l&#39;efecte de la CS sobre el dolor a la c&#224;rrega i sobre l&#39;&#237;ndex Lequesne &#233;s inferior al que s&#39;aconsegueix amb DS&#46;</p><p class="elsevierStylePara">A partir del dia 45 de l&#39;estudi&#44; l&#39;efecte de la CS va ser semblant al del DS&#46; Amb tot&#44; durant els mesos 4&#44; 5 i 6&#44; en qu&#232; els pacients nom&#233;s van prendre placebo&#44; l&#39;efecte va disminuir significativament en el grup del DS&#44; mentre que el grup de la CS va mantenir el seu efecte positiu&#46; Al cap de 6 mesos&#44; la puntuaci&#243; en el grup de la CS va ser un 64&#44;4&#37; inferior als valors inicials&#44; i la del grup del DS&#44; un 29&#44;7&#37; &#40;fig&#46; 2&#41;&#46;</p><p class="elsevierStylePara"><img src="278v42n154-13108859tab02.gif"></img></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Figura 2</span> Valors mitjans de l&#39;&#237;ndex Lequesne durant l&#39;estudi&#46;</p><p class="elsevierStylePara">Un altre estudi<span class="elsevierStyleSup">2</span> ha definit les caracter&#237;stiques de la resposta de la CS durant i despr&#233;s de la seva administraci&#243;&#44; prenent com a refer&#232;ncia l&#39;efecte de 150 mg de DS&#46; Amb aquesta finalitat&#44; es van avaluar diversos assajos cl&#237;nics aleatoritzats&#44; a doble cec&#44; controlats amb placebo&#44; que inclo&#239;en pacients amb artrosi de genoll&#46;</p><p class="elsevierStylePara">L&#39;efecte de la CS sobre l&#39;estatus funcional &#40;&#237;ndex Lequesne&#41;&#44; el dolor espontani &#40;escala anal&#242;gica visual &#91;EAV&#93; de Huskisson&#41; i el dolor a la c&#224;rrega van ser avaluats utilitzant el model Em&#224;x&#46; Aquesta metodologia permet predir l&#39;efecte m&#224;xim que es pot obtenir &#40;E<span class="elsevierStyleInf">m&#224;x</span>&#41;&#44; i el temps exigit per obtenir el 50&#37; de l&#39;E<span class="elsevierStyleInf">m&#224;x</span> &#40;T<span class="elsevierStyleInf">50</span>&#41;&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Resultats</span></p><p class="elsevierStylePara">Els resultats d&#39;aquest estudi &#40;taula I&#41; suggereixen que la resposta m&#233;s favorable predita en pacients amb artrosi de genoll que han rebut 800 mg&#47;dia de CS durant 90 dies &#233;s lleument superior a la predita per al DS&#44; malgrat que la CS triga el doble a aconseguir l&#39;efecte m&#233;s favorable&#46; D&#39;altra banda&#44; l&#39;efecte romanent de la CS persisteix el doble que el del DS&#46;</p><p class="elsevierStylePara"><img src="278v42n154-13108859tab03.gif"></img></p><p class="elsevierStylePara">En total&#44; 9 assajos cl&#237;nics&#44; aleatoritzats&#44; a doble cec&#44; han comparat l&#39;efecte de la CS amb el del placebo en pacients amb artrosi de genoll i dits&#44; tractats durant per&#237;odes que van oscil&#183;lar entre 3 i 36 mesos&#46;</p><p class="elsevierStylePara">Els resultats de tots els assajos cl&#237;nics coincideixen a concloure que la CS &#233;s m&#233;s efica&#231; &#40;aproximadament el 50&#37;&#59; p &#60; 0&#44;05&#41; que el placebo per reduir el dolor espontani&#44; augmentar la capacitat funcional&#44; disminuir la ingesta de medicaci&#243; de rescat i en la valoraci&#243; global del pacient i l&#39;investigador&#46;</p><p class="elsevierStylePara">Igualment&#44; una metaan&#224;lisi<span class="elsevierStyleSup">3</span> recull les dades de 7 assajos cl&#237;nics prou homogenis com per ser analitzats conjuntament&#46; Un total de 703 pacients van ser inclosos en aquests assajos cl&#237;nics&#44; 372 tractats amb CS i 331 amb placebo&#46; L&#39;efecte de la CS sobre el dolor espontani i sobre la capacitat funcional va ser significativament superior al placebo a partir dels 4 mesos&#46; Les avaluacions realitzades pels pacients i els metges demostren que el tractament amb CS &#233;s superior al placebo&#46; Finalment&#44; els pacients tractats amb CS van prendre significativament menys medicaci&#243; de rescat que els pacients que rebien placebo&#46; A m&#233;s&#44; cal destacar que els efectes adversos van ser lleus i m&#233;s elevats en els grups de placebo que en els de CS&#46;</p><p class="elsevierStylePara">Tamb&#233; cal destacar un nou assaig cl&#237;nic recent<span class="elsevierStyleSup">4</span> &#40;GAIT&#44; Glucosamine&#47; Chondroitin Arthritis Intervention Trial&#41; multic&#232;ntric&#44; aleatoritzat i doble cec en un total de 1&#46;583 pacients amb artrosi de genoll&#44; en el qual es va estudiar l&#39;efecte de 5 tractaments &#40;500 mg de glucosamina 3 vegades al dia&#59; 400 mg de CS 3 vegades al dia&#59; 200 mg de celecoxib al dia&#59; 500 mg de glucosamina &#43; 400 mg de CS 3 vegades al dia&#59; placebo&#41; sobre la reducci&#243; del dolor durant 6 mesos&#46;</p><p class="elsevierStylePara">En aquest assaig cl&#237;nic es va observar una disminuci&#243; significativa de la inflamaci&#243;&#44; acompanyada o no de vessament articular &#40;sinovitis&#41;&#44; en el grup tractat amb CS&#44; comparat amb placebo &#40;p &#61; 0&#44;01&#41;&#46;</p><p class="elsevierStylePara">Clegg et al<span class="elsevierStyleSup">5</span><span class="elsevierStyleItalic">&#44;</span> basant-se en el mateix estudi &#40;GAIT&#41;&#44; tamb&#233; van avaluar si la CS podria tenir un efecte diferencial sobre els s&#237;mptomes de l&#39;artrosi quant al grau radiogr&#224;fic de Kellgren &#38; Lawrence &#40;KL&#41; dels pacients&#46; Els resultats suggereixen que la CS podria millorar el dolor de l&#39;artrosi de genoll en pacients amb fases inicials de la patologia&#44; en concret amb grau 2 de KL&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold"> Conclusi&#243;</span></p><p class="elsevierStylePara">En definitiva&#44; podem concloure que la CS &#233;s una eina terap&#232;utica de gran utilitat per al tractament de l&#39;artrosi&#46;</p><hr></hr><p class="elsevierStylePara">Correspond&#232;ncia&#58; BIOIBERICA&#44; SA&#46; P&#231;a&#46; Francesc Maci&#224;&#44; 7&#46; 08029 Barcelona&#46; Espanya&#46;<br></br> Correu electr&#242;nic&#58; <a href="mailto&#58;jverges&#64;bioiberica&#46;com" class="elsevierStyleCrossRefs"> jverges&#64;bioiberica&#46;com</a></p>"
    "pdfFichero" => "278v42n154a13108859pdf001.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec938018"
          "palabras" => array:3 [
            0 => "Condro&#239;tina sulfat"
            1 => "Artrosi"
            2 => "SYSADOA"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec938019"
          "palabras" => array:3 [
            0 => "Chondroitin sulfate"
            1 => "Osteoarthritis"
            2 => "SYSADOA"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<span class="elsevierStyleBold">Introducci&#243;&#58;</span> La condro&#239;tina sulfat pertany al grup dels f&#224;rmacs d&#39;acci&#243; simptom&#224;tica lenta &#40;SYSADOA&#41;&#44; que es caracteritzen pel fet de presentar una efic&#224;cia sobre els s&#237;mptomes semblant a la dels antiinflamatoris no estero&#239;dals&#44; que comen&#231;a d&#39;una manera gradual per&#242; que es perllonga m&#233;s enll&#224; de la supressi&#243; del tractament&#46; <span class="elsevierStyleBold">Material i m&#232;todes&#58;</span> En total 9 assajos cl&#237;nics&#44; aleatoritzats&#44; a doble cec&#44; han comparat l&#39;efecte de la condro&#239;tina sulfat amb el del placebo i&#44; en un cas&#44; amb el del diclofenac s&#242;dic &#40;150 mg&#47;dia&#41; en pacients amb artrosi de genoll i dits&#44; tractats durant per&#237;odes que van oscil&#183;lar entre 3 i 36 mesos&#46; <span class="elsevierStyleBold">Resultats&#58;</span> Els resultats de tots els assajos cl&#237;nics coincideixen a concloure que la condro&#239;tina sulfat &#233;s m&#233;s efica&#231; &#40;aproximadament el 50&#37;&#59; p &#60; 0&#44;05&#41; que el placebo per reduir el dolor espontani&#44; augmentar la capacitat funcional&#44; disminuir la ingesta de medicaci&#243; de rescat i en la valoraci&#243; global del pacient i l&#39;investigador&#46; Al mateix temps&#44; els resultats tamb&#233; confirmen l&#39;elevat perfil de seguretat del producte&#46; En un nou assaig cl&#237;nic realitzat en un total de 1&#46;583 pacients amb artrosi de genoll&#44; en el qual es va estudiar l&#39;efecte de la glucosamina &#40;1&#46;500 mg&#47;dia&#41;&#44; de la condro&#239;tina sulfat &#40;1&#46;200 mg&#47;dia&#41; i de la seva associaci&#243; davant de celecoxib &#40;200 mg&#47;dia&#41; i placebo durant un per&#237;ode de 6 mesos&#44; es va observar una disminuci&#243; significativa de la inflamaci&#243;&#44; acompanyada o no de vessament articular&#44; en el grup tractat amb condro&#239;tina sulfat&#44; respecte de placebo &#40;p &#61; 0&#44;01&#41;&#46; <span class="elsevierStyleBold">Conclusi&#243;&#58;</span> En definitiva&#44; es pot concloure que la condro&#239;tina sulfat &#233;s una eina terap&#232;utica de gran utilitat per al tractament de l&#39;artrosi&#46;"
      ]
      "en" => array:1 [
        "resumen" => "<span class="elsevierStyleBold">Introduction&#58;</span> Chondroitin sulfate belongs to the group of symptomatic slow-acting drugs for osteoarthritis &#40;SYSADOA&#41;&#46; The efficacy of this drug on symptoms is similar to that of non-steroidal anti-inflammatory agents&#44; the effect starting gradually but persisting after treatment suppression&#46; <span class="elsevierStyleBold">Materials and methods&#58;</span> We analyzed randomized&#44; double-blind clinical trials that compared the effect of chondroitin sulfate with that placebo and&#44; in one trial&#44; with sodium diclofenac &#40;150 mg&#47;day&#41; in patients with knee and finger osteoarthritis treated for periods ranging from 3 to 36 months&#46; <span class="elsevierStyleBold">Results&#58;</span> The results of all the clinical trials indicate that chondroitin sulfate is more effective &#40;by approximately 50&#37;&#44; p &#60; 0&#46;05&#41; than placebo in reducing spontaneous pain&#44; increasing joint function&#44; and reducing rescue medication&#59; in addition overall patient and physician assessment was higher&#46; Equally&#44; the trials confirm the high safety profile of the drug&#46; A new clinical trial conducted in 1&#44;583 patients with knee osteoarthritis&#44; which studied the effect of glucosamine &#40;1&#44;500 mg &#47;day&#41;&#44; chondroitin sulfate &#40;1&#44;200 mg &#47;day&#41; and their association in comparison with celecoxib &#40;200 mg&#47; day&#41; and placebo for 6 months found a significant reduction of joint swelling&#44; with or without joint effusion&#44; for the chondroitin sulfate group compared with the placebo group &#40;p &#61; 0&#46;01&#41;&#46; <span class="elsevierStyleBold">Conclusion&#58;</span> Chondroitin sulfate is a highly useful therapeutic tool for the treatment of osteoarthritis&#46;"
      ]
    ]
    "multimedia" => array:6 [
      0 => array:8 [
        "identificador" => "tbl1"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "278v42n154-13108859tab01.gif"
                  "imagenAlto" => 570
                  "imagenAncho" => 700
                  "imagenTamanyo" => 453221
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "ct" => "Efecte anti&#224;lgic i funcional del diclofenac s&#242;dic&#44; 150 mg&#47;dia durant 30 dies&#44; i de la condro&#239;tina sulfat &#40;CS&#41; 1&#46;200 mg durant 90 dies&#44; mesurats als 30&#44; 45&#44; 60 i 90 dies&#46; &#42;p &#60; 0&#44;05 respecte del diclofenac&#46;"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl2"
        "etiqueta" => "Figura 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "278v42n154-13108859tab02.gif"
                  "imagenAlto" => 454
                  "imagenAncho" => 700
                  "imagenTamanyo" => 361151
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "ct" => "Valors mitjans de l&#39;&#237;ndex Lequesne durant l&#39;estudi&#46;"
        ]
      ]
      2 => array:7 [
        "identificador" => "tbl3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "278v42n154-13108859tab03.gif"
                  "imagenAlto" => 1017
                  "imagenAncho" => 700
                  "imagenTamanyo" => 808010
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "ct" => "Taula 1 Par&#224;metres farmacodin&#224;mics de predicci&#243; per a la condro&#239;tina sulfat administrada amb la dosi de 1&#46;200 mg&#47;dia durant 90 dies i el diclofenac s&#242;dic administrat amb la dosi de 150 mg&#47;dia durant 30 dies en pacients amb artrosi de genoll&#46; &#40;Dades de Morreale et al1&#41;"
        ]
      ]
      3 => array:5 [
        "identificador" => "tbl4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
      ]
      4 => array:5 [
        "identificador" => "tbl5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
      ]
      5 => array:5 [
        "identificador" => "tbl6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf¿a"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:5 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 1996;23:1385-91."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Morreale P"
                            1 => "Manopulo R"
                            2 => "Galati M"
                            3 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol"
                        "fecha" => "1996"
                        "volumen" => "23"
                        "paginaInicial" => "1385"
                        "paginaFinal" => "91"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8856618"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Simple approach to predict Emax when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. Clin Pharmacol Ther. 2001;70:5-9."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Simple approach to predict Emax when plasma concentrations are not available or are dissociated from the effect&#44; as illustrated with chondroitin sulfate data&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Du Souich P"
                            1 => "Verg&#233;s J&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1067/mcp.2001.116977"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Pharmacol Ther"
                        "fecha" => "2001"
                        "volumen" => "70"
                        "paginaInicial" => "5"
                        "paginaFinal" => "9"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11452238"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol. 2000;27:205-11."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Leeb BF"
                            1 => "Schweitzer H"
                            2 => "Montag K"
                            3 => "Smolen JS&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol"
                        "fecha" => "2000"
                        "volumen" => "27"
                        "paginaInicial" => "205"
                        "paginaFinal" => "11"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10648040"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354:795-808."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Glucosamine&#44; chondroitin sulfate&#44; and the two in combination for painful knee osteoarthritis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:8 [
                            0 => "Clegg DO"
                            1 => "Reda DJ"
                            2 => "Harris CL"
                            3 => "Klein MA"
                            4 => "O&#39;Del&#46;l"
                            5 => "JR"
                            6 => "Hooper MM"
                            7 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa052771"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2006"
                        "volumen" => "354"
                        "paginaInicial" => "795"
                        "paginaFinal" => "808"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16495392"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "referenciaCompleta" => "Chondroitin sulfate may have differential effects on OA symptoms related to degree of radiographic involvement. Osteoarthritis Cartilage. 2005;13 Suppl A:145."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Chondroitin sulfate may have differential effects on OA symptoms related to degree of radiographic involvement&#46; Osteoarthritis Cartilage&#46; 2005&#59;13 Suppl A&#58;145&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Clegg DO"
                            1 => "Reda DJ"
                            2 => "Hooper MM"
                            3 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "ct"
  "url" => "/X8866581/0000004200000154/v0_201801081416/XX886658107088599/v0_201801081416/ct/main.assets"
  "Apartado" => array:4 [
    "identificador" => "71856"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Treballs originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/X8866581/0000004200000154/v0_201801081416/XX886658107088599/v0_201801081416/ct/278v42n154a13108859pdf001.pdf?idApp=UINPBA00004N&text.app=https://apunts.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088599?idApp=UINPBA00004N"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Utilitat clínica de la condroïtina sulfat
Clinical utility of condroitin sulfate
Josep Vergésa
a Facultad de Medicina. Universidad Autónoma de Madrid. Madrid. Espanya.
Read
7059
Times
was read the article
2780
Total PDF
4279
Total HTML
Share statistics
 array:20 [
  "pii" => "XX886658107088599"
  "issn" => "X8866581"
  "estado" => "S300"
  "fechaPublicacion" => "2007-04-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Apunts&#46; Medicina de l&#39;Esport. 2007;42:88-91"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 3330
    "formatos" => array:3 [
      "EPUB" => 157
      "HTML" => 2011
      "PDF" => 1162
    ]
  ]
  "Traduccion" => array:2 [
    "en" => array:16 [
      "pii" => "13108884"
      "issn" => "18866581"
      "estado" => "S300"
      "fechaPublicacion" => "2007-04-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Apunts&#46; Medicina de l&#39;Esport. 2007;42:88-91"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:2 [
        "total" => 1477
        "formatos" => array:3 [
          "EPUB" => 146
          "HTML" => 1261
          "PDF" => 70
        ]
      ]
      "en" => array:7 [
        "idiomaDefecto" => true
        "titulo" => "Clinical utility of condroitin sulfate"
        "tieneTextoCompleto" => 0
        "tieneResumen" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "88"
            "paginaFinal" => "91"
          ]
        ]
        "contieneResumen" => array:1 [
          "en" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Josep Verg&#233;s"
            "autores" => array:1 [
              0 => array:2 [
                "nombre" => "Josep"
                "apellidos" => "Verg&#233;s"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "ct" => array:8 [
          "pii" => "XX886658107088599"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "ct"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088599?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13108884?idApp=UINPBA00004N"
      "url" => "/18866581/0000004200000154/v0_201801081334/13108884/v0_201801081334/en/main.assets"
    ]
    "es" => array:16 [
      "pii" => "X0213371707088843"
      "issn" => "02133717"
      "estado" => "S300"
      "fechaPublicacion" => "2007-04-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Apunts&#46; Medicina de l&#39;Esport. 2007;42:88-91"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:2 [
        "total" => 3220
        "formatos" => array:3 [
          "EPUB" => 137
          "HTML" => 2029
          "PDF" => 1054
        ]
      ]
      "es" => array:11 [
        "idiomaDefecto" => true
        "titulo" => "Utilidad cl&#237;nica del condroit&#237;n sulfato"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "88"
            "paginaFinal" => "91"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Clinical utility of condroitin sulfate"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Josep Verg&#233;s"
            "autores" => array:1 [
              0 => array:2 [
                "nombre" => "Josep"
                "apellidos" => "Verg&#233;s"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "ct" => array:8 [
          "pii" => "XX886658107088599"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "ct"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088599?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0213371707088843?idApp=UINPBA00004N"
      "url" => "/02133717/0000004200000154/v0_201801081434/X0213371707088843/v0_201801081434/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:16 [
    "pii" => "XX886658107088603"
    "issn" => "X8866581"
    "estado" => "S300"
    "fechaPublicacion" => "2007-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Apunts&#46; Medicina de l&#39;Esport. 2007;42:92-8"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 3463
      "formatos" => array:3 [
        "EPUB" => 164
        "HTML" => 2235
        "PDF" => 1064
      ]
    ]
    "ct" => array:11 [
      "idiomaDefecto" => true
      "titulo" => "Esport i massa &#242;ssia &#40;II&#41;&#46; Caracter&#237;stiques de l&#39;exercici f&#237;sic que condicionen el modelatge i el remodelatge ossis"
      "tienePdf" => "ct"
      "tieneTextoCompleto" => "ct"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "92"
          "paginaFinal" => "98"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Sports activity and bone mas &#40;II&#41;&#46; The characteristics of physical activity that affect bone formation and remodeling"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "ct" => true
      ]
      "contienePdf" => array:1 [
        "ct" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Caritat Bagur Calafat"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Caritat"
              "apellidos" => "Bagur Calafat"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "ct"
    "Traduccion" => array:2 [
      "en" => array:8 [
        "pii" => "13108885"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13108885?idApp=UINPBA00004N"
      ]
      "es" => array:8 [
        "pii" => "X0213371707088851"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0213371707088851?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088603?idApp=UINPBA00004N"
    "url" => "/X8866581/0000004200000154/v0_201801081416/XX886658107088603/v0_201801081416/ct/main.assets"
  ]
  "itemAnterior" => array:16 [
    "pii" => "XX886658107088580"
    "issn" => "X8866581"
    "estado" => "S300"
    "fechaPublicacion" => "2007-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Apunts&#46; Medicina de l&#39;Esport. 2007;42:82-7"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 3654
      "formatos" => array:3 [
        "EPUB" => 136
        "HTML" => 2360
        "PDF" => 1158
      ]
    ]
    "ct" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Valoraci&#243; de la for&#231;a &#250;til en tennis"
      "tienePdf" => "ct"
      "tieneTextoCompleto" => "ct"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "82"
          "paginaFinal" => "87"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Evaluation of useful force in tennis"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "ct" => true
      ]
      "contienePdf" => array:1 [
        "ct" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "278v42n154-13108858fig01.jpg"
              "Alto" => 524
              "Ancho" => 700
              "Tamanyo" => 102348
            ]
          ]
          "descripcion" => array:1 [
            "ct" => "Cop de dreta en el tennis&#46;"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ra&#250;l Pablo Garrido Chamorro, Cristina Blasco Lafarga, Alejandro Ricardo Albert Gim&#233;nez, Emilio Jos&#233; Poveda Pag&#225;n, Jes&#250;s Mas Mart&#237;nez"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Ra&#250;l Pablo"
              "apellidos" => "Garrido Chamorro"
            ]
            1 => array:2 [
              "nombre" => "Cristina"
              "apellidos" => "Blasco Lafarga"
            ]
            2 => array:2 [
              "nombre" => "Alejandro Ricardo"
              "apellidos" => "Albert Gim&#233;nez"
            ]
            3 => array:2 [
              "nombre" => "Emilio Jos&#233;"
              "apellidos" => "Poveda Pag&#225;n"
            ]
            4 => array:2 [
              "nombre" => "Jes&#250;s"
              "apellidos" => "Mas Mart&#237;nez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "ct"
    "Traduccion" => array:2 [
      "en" => array:8 [
        "pii" => "13108883"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13108883?idApp=UINPBA00004N"
      ]
      "es" => array:8 [
        "pii" => "X0213371707088835"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0213371707088835?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088580?idApp=UINPBA00004N"
    "url" => "/X8866581/0000004200000154/v0_201801081416/XX886658107088580/v0_201801081416/ct/main.assets"
  ]
  "ct" => array:14 [
    "idiomaDefecto" => true
    "titulo" => "Utilitat cl&#237;nica de la condro&#239;tina sulfat"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "88"
        "paginaFinal" => "91"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Josep Verg&#233;s"
        "autores" => array:1 [
          0 => array:3 [
            "nombre" => "Josep"
            "apellidos" => "Verg&#233;s"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:3 [
            "entidad" => "Facultad de Medicina&#46; Universidad Aut&#243;noma de Madrid&#46; Madrid&#46; Espanya&#46;"
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Clinical utility of condroitin sulfate"
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold"> Introducci&#243;</span></p><p class="elsevierStylePara">La condro&#239;tina sulfat &#40;CS&#41; pertany al grup dels f&#224;rmacs d&#39;acci&#243; simptom&#224;tica lenta &#40;SYSADOA&#44; <span class="elsevierStyleItalic">symptomatic slow acting drug for osteoarthritis</span>&#41; caracteritzats perqu&#232; presenten una efic&#224;cia sobre els s&#237;mptomes semblant a la dels antiinflamatoris no estero&#239;dals &#40;AINE&#41; que comen&#231;a d&#39;una manera gradual per&#242; que es perllonga durant m&#233;s temps&#44; fins i tot despr&#233;s de la supressi&#243; del tractament &#40;efecte persistent o <span class="elsevierStyleItalic">carry over</span>&#41;&#46; Igualment&#44; es tracta de productes d&#39;una gran seguretat&#46;</p><p class="elsevierStylePara">Els assajos cl&#237;nics en pacients artr&#242;sics demostren que el tractament amb CS produeix una disminuci&#243; o desaparici&#243; dels s&#237;mptomes de la malaltia artr&#242;sica&#44; com s&#243;n el dolor i la impot&#232;ncia funcional&#44; i millora el moviment de les articulacions afectades&#44; amb un efecte que perdura 2 o 3 mesos&#46;</p><p class="elsevierStylePara">Com que es tracta d&#39;un f&#224;rmac d&#39;acci&#243; simptom&#224;tica lenta &#40;SYSADOA&#41;&#44; l&#39;inici d&#39;acci&#243; de la CS &#233;s una mica lent&#44; entre 2-3 setmanes&#44; per b&#233; que eventualment aconsegueix la mateixa efic&#224;cia que els antiinflamatoris&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Material i m&#232;todes</span></p><p class="elsevierStylePara">Per determinar l&#39;efic&#224;cia de la CS en el tractament simptom&#224;tic de l&#39;artrosi&#44; s&#39;han fet diversos assajos cl&#237;nics que posen de manifest la seva utilitat arran d&#39;aquesta afecci&#243;&#46; Tot seguit es resumeixen les evid&#232;ncies cl&#237;niques disponibles amb CS&#46;</p><p class="elsevierStylePara">S&#39;ha fet un assaig cl&#237;nic aleatoritzat&#44; multic&#232;ntric&#44; a doble cec&#44; amb 146 pacients amb artrosi del genoll i de 6 mesos de durada&#44; comparant el diclofenac s&#242;dic &#40;DS&#41; pres durant 30 dies respecte de la CS presa durant 90 dies<span class="elsevierStyleSup">1</span>&#46; Els resultats estan resumits en la figura 1&#46;</p><p class="elsevierStylePara"><img src="278v42n154-13108859tab01.gif"></img></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Figura 1</span> Efecte anti&#224;lgic i funcional del diclofenac s&#242;dic&#44; 150 mg&#47;dia durant 30 dies&#44; i de la condro&#239;tina sulfat &#40;CS&#41; 1&#46;200 mg durant 90 dies&#44; mesurats als 30&#44; 45&#44; 60 i 90 dies&#46; &#42;p &#60; 0&#44;05 respecte del diclofenac&#46;</p><p class="elsevierStylePara">Tenint en compte &#250;nicament les mesures de dolor i funcionals als 30 dies de tractament&#44; es pot concloure que la CS fa minvar el dolor espontani amb la mateixa efic&#224;cia que el DS&#46; Per&#242; als 30 dies de tractament&#44; l&#39;efecte de la CS sobre el dolor a la c&#224;rrega i sobre l&#39;&#237;ndex Lequesne &#233;s inferior al que s&#39;aconsegueix amb DS&#46;</p><p class="elsevierStylePara">A partir del dia 45 de l&#39;estudi&#44; l&#39;efecte de la CS va ser semblant al del DS&#46; Amb tot&#44; durant els mesos 4&#44; 5 i 6&#44; en qu&#232; els pacients nom&#233;s van prendre placebo&#44; l&#39;efecte va disminuir significativament en el grup del DS&#44; mentre que el grup de la CS va mantenir el seu efecte positiu&#46; Al cap de 6 mesos&#44; la puntuaci&#243; en el grup de la CS va ser un 64&#44;4&#37; inferior als valors inicials&#44; i la del grup del DS&#44; un 29&#44;7&#37; &#40;fig&#46; 2&#41;&#46;</p><p class="elsevierStylePara"><img src="278v42n154-13108859tab02.gif"></img></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Figura 2</span> Valors mitjans de l&#39;&#237;ndex Lequesne durant l&#39;estudi&#46;</p><p class="elsevierStylePara">Un altre estudi<span class="elsevierStyleSup">2</span> ha definit les caracter&#237;stiques de la resposta de la CS durant i despr&#233;s de la seva administraci&#243;&#44; prenent com a refer&#232;ncia l&#39;efecte de 150 mg de DS&#46; Amb aquesta finalitat&#44; es van avaluar diversos assajos cl&#237;nics aleatoritzats&#44; a doble cec&#44; controlats amb placebo&#44; que inclo&#239;en pacients amb artrosi de genoll&#46;</p><p class="elsevierStylePara">L&#39;efecte de la CS sobre l&#39;estatus funcional &#40;&#237;ndex Lequesne&#41;&#44; el dolor espontani &#40;escala anal&#242;gica visual &#91;EAV&#93; de Huskisson&#41; i el dolor a la c&#224;rrega van ser avaluats utilitzant el model Em&#224;x&#46; Aquesta metodologia permet predir l&#39;efecte m&#224;xim que es pot obtenir &#40;E<span class="elsevierStyleInf">m&#224;x</span>&#41;&#44; i el temps exigit per obtenir el 50&#37; de l&#39;E<span class="elsevierStyleInf">m&#224;x</span> &#40;T<span class="elsevierStyleInf">50</span>&#41;&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Resultats</span></p><p class="elsevierStylePara">Els resultats d&#39;aquest estudi &#40;taula I&#41; suggereixen que la resposta m&#233;s favorable predita en pacients amb artrosi de genoll que han rebut 800 mg&#47;dia de CS durant 90 dies &#233;s lleument superior a la predita per al DS&#44; malgrat que la CS triga el doble a aconseguir l&#39;efecte m&#233;s favorable&#46; D&#39;altra banda&#44; l&#39;efecte romanent de la CS persisteix el doble que el del DS&#46;</p><p class="elsevierStylePara"><img src="278v42n154-13108859tab03.gif"></img></p><p class="elsevierStylePara">En total&#44; 9 assajos cl&#237;nics&#44; aleatoritzats&#44; a doble cec&#44; han comparat l&#39;efecte de la CS amb el del placebo en pacients amb artrosi de genoll i dits&#44; tractats durant per&#237;odes que van oscil&#183;lar entre 3 i 36 mesos&#46;</p><p class="elsevierStylePara">Els resultats de tots els assajos cl&#237;nics coincideixen a concloure que la CS &#233;s m&#233;s efica&#231; &#40;aproximadament el 50&#37;&#59; p &#60; 0&#44;05&#41; que el placebo per reduir el dolor espontani&#44; augmentar la capacitat funcional&#44; disminuir la ingesta de medicaci&#243; de rescat i en la valoraci&#243; global del pacient i l&#39;investigador&#46;</p><p class="elsevierStylePara">Igualment&#44; una metaan&#224;lisi<span class="elsevierStyleSup">3</span> recull les dades de 7 assajos cl&#237;nics prou homogenis com per ser analitzats conjuntament&#46; Un total de 703 pacients van ser inclosos en aquests assajos cl&#237;nics&#44; 372 tractats amb CS i 331 amb placebo&#46; L&#39;efecte de la CS sobre el dolor espontani i sobre la capacitat funcional va ser significativament superior al placebo a partir dels 4 mesos&#46; Les avaluacions realitzades pels pacients i els metges demostren que el tractament amb CS &#233;s superior al placebo&#46; Finalment&#44; els pacients tractats amb CS van prendre significativament menys medicaci&#243; de rescat que els pacients que rebien placebo&#46; A m&#233;s&#44; cal destacar que els efectes adversos van ser lleus i m&#233;s elevats en els grups de placebo que en els de CS&#46;</p><p class="elsevierStylePara">Tamb&#233; cal destacar un nou assaig cl&#237;nic recent<span class="elsevierStyleSup">4</span> &#40;GAIT&#44; Glucosamine&#47; Chondroitin Arthritis Intervention Trial&#41; multic&#232;ntric&#44; aleatoritzat i doble cec en un total de 1&#46;583 pacients amb artrosi de genoll&#44; en el qual es va estudiar l&#39;efecte de 5 tractaments &#40;500 mg de glucosamina 3 vegades al dia&#59; 400 mg de CS 3 vegades al dia&#59; 200 mg de celecoxib al dia&#59; 500 mg de glucosamina &#43; 400 mg de CS 3 vegades al dia&#59; placebo&#41; sobre la reducci&#243; del dolor durant 6 mesos&#46;</p><p class="elsevierStylePara">En aquest assaig cl&#237;nic es va observar una disminuci&#243; significativa de la inflamaci&#243;&#44; acompanyada o no de vessament articular &#40;sinovitis&#41;&#44; en el grup tractat amb CS&#44; comparat amb placebo &#40;p &#61; 0&#44;01&#41;&#46;</p><p class="elsevierStylePara">Clegg et al<span class="elsevierStyleSup">5</span><span class="elsevierStyleItalic">&#44;</span> basant-se en el mateix estudi &#40;GAIT&#41;&#44; tamb&#233; van avaluar si la CS podria tenir un efecte diferencial sobre els s&#237;mptomes de l&#39;artrosi quant al grau radiogr&#224;fic de Kellgren &#38; Lawrence &#40;KL&#41; dels pacients&#46; Els resultats suggereixen que la CS podria millorar el dolor de l&#39;artrosi de genoll en pacients amb fases inicials de la patologia&#44; en concret amb grau 2 de KL&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold"> Conclusi&#243;</span></p><p class="elsevierStylePara">En definitiva&#44; podem concloure que la CS &#233;s una eina terap&#232;utica de gran utilitat per al tractament de l&#39;artrosi&#46;</p><hr></hr><p class="elsevierStylePara">Correspond&#232;ncia&#58; BIOIBERICA&#44; SA&#46; P&#231;a&#46; Francesc Maci&#224;&#44; 7&#46; 08029 Barcelona&#46; Espanya&#46;<br></br> Correu electr&#242;nic&#58; <a href="mailto&#58;jverges&#64;bioiberica&#46;com" class="elsevierStyleCrossRefs"> jverges&#64;bioiberica&#46;com</a></p>"
    "pdfFichero" => "278v42n154a13108859pdf001.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec938018"
          "palabras" => array:3 [
            0 => "Condro&#239;tina sulfat"
            1 => "Artrosi"
            2 => "SYSADOA"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec938019"
          "palabras" => array:3 [
            0 => "Chondroitin sulfate"
            1 => "Osteoarthritis"
            2 => "SYSADOA"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<span class="elsevierStyleBold">Introducci&#243;&#58;</span> La condro&#239;tina sulfat pertany al grup dels f&#224;rmacs d&#39;acci&#243; simptom&#224;tica lenta &#40;SYSADOA&#41;&#44; que es caracteritzen pel fet de presentar una efic&#224;cia sobre els s&#237;mptomes semblant a la dels antiinflamatoris no estero&#239;dals&#44; que comen&#231;a d&#39;una manera gradual per&#242; que es perllonga m&#233;s enll&#224; de la supressi&#243; del tractament&#46; <span class="elsevierStyleBold">Material i m&#232;todes&#58;</span> En total 9 assajos cl&#237;nics&#44; aleatoritzats&#44; a doble cec&#44; han comparat l&#39;efecte de la condro&#239;tina sulfat amb el del placebo i&#44; en un cas&#44; amb el del diclofenac s&#242;dic &#40;150 mg&#47;dia&#41; en pacients amb artrosi de genoll i dits&#44; tractats durant per&#237;odes que van oscil&#183;lar entre 3 i 36 mesos&#46; <span class="elsevierStyleBold">Resultats&#58;</span> Els resultats de tots els assajos cl&#237;nics coincideixen a concloure que la condro&#239;tina sulfat &#233;s m&#233;s efica&#231; &#40;aproximadament el 50&#37;&#59; p &#60; 0&#44;05&#41; que el placebo per reduir el dolor espontani&#44; augmentar la capacitat funcional&#44; disminuir la ingesta de medicaci&#243; de rescat i en la valoraci&#243; global del pacient i l&#39;investigador&#46; Al mateix temps&#44; els resultats tamb&#233; confirmen l&#39;elevat perfil de seguretat del producte&#46; En un nou assaig cl&#237;nic realitzat en un total de 1&#46;583 pacients amb artrosi de genoll&#44; en el qual es va estudiar l&#39;efecte de la glucosamina &#40;1&#46;500 mg&#47;dia&#41;&#44; de la condro&#239;tina sulfat &#40;1&#46;200 mg&#47;dia&#41; i de la seva associaci&#243; davant de celecoxib &#40;200 mg&#47;dia&#41; i placebo durant un per&#237;ode de 6 mesos&#44; es va observar una disminuci&#243; significativa de la inflamaci&#243;&#44; acompanyada o no de vessament articular&#44; en el grup tractat amb condro&#239;tina sulfat&#44; respecte de placebo &#40;p &#61; 0&#44;01&#41;&#46; <span class="elsevierStyleBold">Conclusi&#243;&#58;</span> En definitiva&#44; es pot concloure que la condro&#239;tina sulfat &#233;s una eina terap&#232;utica de gran utilitat per al tractament de l&#39;artrosi&#46;"
      ]
      "en" => array:1 [
        "resumen" => "<span class="elsevierStyleBold">Introduction&#58;</span> Chondroitin sulfate belongs to the group of symptomatic slow-acting drugs for osteoarthritis &#40;SYSADOA&#41;&#46; The efficacy of this drug on symptoms is similar to that of non-steroidal anti-inflammatory agents&#44; the effect starting gradually but persisting after treatment suppression&#46; <span class="elsevierStyleBold">Materials and methods&#58;</span> We analyzed randomized&#44; double-blind clinical trials that compared the effect of chondroitin sulfate with that placebo and&#44; in one trial&#44; with sodium diclofenac &#40;150 mg&#47;day&#41; in patients with knee and finger osteoarthritis treated for periods ranging from 3 to 36 months&#46; <span class="elsevierStyleBold">Results&#58;</span> The results of all the clinical trials indicate that chondroitin sulfate is more effective &#40;by approximately 50&#37;&#44; p &#60; 0&#46;05&#41; than placebo in reducing spontaneous pain&#44; increasing joint function&#44; and reducing rescue medication&#59; in addition overall patient and physician assessment was higher&#46; Equally&#44; the trials confirm the high safety profile of the drug&#46; A new clinical trial conducted in 1&#44;583 patients with knee osteoarthritis&#44; which studied the effect of glucosamine &#40;1&#44;500 mg &#47;day&#41;&#44; chondroitin sulfate &#40;1&#44;200 mg &#47;day&#41; and their association in comparison with celecoxib &#40;200 mg&#47; day&#41; and placebo for 6 months found a significant reduction of joint swelling&#44; with or without joint effusion&#44; for the chondroitin sulfate group compared with the placebo group &#40;p &#61; 0&#46;01&#41;&#46; <span class="elsevierStyleBold">Conclusion&#58;</span> Chondroitin sulfate is a highly useful therapeutic tool for the treatment of osteoarthritis&#46;"
      ]
    ]
    "multimedia" => array:6 [
      0 => array:8 [
        "identificador" => "tbl1"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "278v42n154-13108859tab01.gif"
                  "imagenAlto" => 570
                  "imagenAncho" => 700
                  "imagenTamanyo" => 453221
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "ct" => "Efecte anti&#224;lgic i funcional del diclofenac s&#242;dic&#44; 150 mg&#47;dia durant 30 dies&#44; i de la condro&#239;tina sulfat &#40;CS&#41; 1&#46;200 mg durant 90 dies&#44; mesurats als 30&#44; 45&#44; 60 i 90 dies&#46; &#42;p &#60; 0&#44;05 respecte del diclofenac&#46;"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl2"
        "etiqueta" => "Figura 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "278v42n154-13108859tab02.gif"
                  "imagenAlto" => 454
                  "imagenAncho" => 700
                  "imagenTamanyo" => 361151
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "ct" => "Valors mitjans de l&#39;&#237;ndex Lequesne durant l&#39;estudi&#46;"
        ]
      ]
      2 => array:7 [
        "identificador" => "tbl3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tablaImagen" => array:1 [
                0 => array:4 [
                  "imagenFichero" => "278v42n154-13108859tab03.gif"
                  "imagenAlto" => 1017
                  "imagenAncho" => 700
                  "imagenTamanyo" => 808010
                ]
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "ct" => "Taula 1 Par&#224;metres farmacodin&#224;mics de predicci&#243; per a la condro&#239;tina sulfat administrada amb la dosi de 1&#46;200 mg&#47;dia durant 90 dies i el diclofenac s&#242;dic administrat amb la dosi de 150 mg&#47;dia durant 30 dies en pacients amb artrosi de genoll&#46; &#40;Dades de Morreale et al1&#41;"
        ]
      ]
      3 => array:5 [
        "identificador" => "tbl4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
      ]
      4 => array:5 [
        "identificador" => "tbl5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
      ]
      5 => array:5 [
        "identificador" => "tbl6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf¿a"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:5 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 1996;23:1385-91."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Morreale P"
                            1 => "Manopulo R"
                            2 => "Galati M"
                            3 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol"
                        "fecha" => "1996"
                        "volumen" => "23"
                        "paginaInicial" => "1385"
                        "paginaFinal" => "91"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8856618"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Simple approach to predict Emax when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. Clin Pharmacol Ther. 2001;70:5-9."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Simple approach to predict Emax when plasma concentrations are not available or are dissociated from the effect&#44; as illustrated with chondroitin sulfate data&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Du Souich P"
                            1 => "Verg&#233;s J&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1067/mcp.2001.116977"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Pharmacol Ther"
                        "fecha" => "2001"
                        "volumen" => "70"
                        "paginaInicial" => "5"
                        "paginaFinal" => "9"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11452238"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol. 2000;27:205-11."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Leeb BF"
                            1 => "Schweitzer H"
                            2 => "Montag K"
                            3 => "Smolen JS&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol"
                        "fecha" => "2000"
                        "volumen" => "27"
                        "paginaInicial" => "205"
                        "paginaFinal" => "11"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10648040"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354:795-808."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Glucosamine&#44; chondroitin sulfate&#44; and the two in combination for painful knee osteoarthritis&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:8 [
                            0 => "Clegg DO"
                            1 => "Reda DJ"
                            2 => "Harris CL"
                            3 => "Klein MA"
                            4 => "O&#39;Del&#46;l"
                            5 => "JR"
                            6 => "Hooper MM"
                            7 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa052771"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2006"
                        "volumen" => "354"
                        "paginaInicial" => "795"
                        "paginaFinal" => "808"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16495392"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "referenciaCompleta" => "Chondroitin sulfate may have differential effects on OA symptoms related to degree of radiographic involvement. Osteoarthritis Cartilage. 2005;13 Suppl A:145."
                  "contribucion" => array:1 [
                    0 => array:3 [
                      "titulo" => "Chondroitin sulfate may have differential effects on OA symptoms related to degree of radiographic involvement&#46; Osteoarthritis Cartilage&#46; 2005&#59;13 Suppl A&#58;145&#46;"
                      "idioma" => "en"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Clegg DO"
                            1 => "Reda DJ"
                            2 => "Hooper MM"
                            3 => "et al&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "ct"
  "url" => "/X8866581/0000004200000154/v0_201801081416/XX886658107088599/v0_201801081416/ct/main.assets"
  "Apartado" => array:4 [
    "identificador" => "71856"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Treballs originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/X8866581/0000004200000154/v0_201801081416/XX886658107088599/v0_201801081416/ct/278v42n154a13108859pdf001.pdf?idApp=UINPBA00004N&text.app=https://apunts.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/XX886658107088599?idApp=UINPBA00004N"
]
Article information
ISSN: X8866581
Original language: Català
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 6 5 11
2024 October 55 27 82
2024 September 55 22 77
2024 August 69 27 96
2024 July 53 35 88
2024 June 44 23 67
2024 May 65 32 97
2024 April 45 32 77
2024 March 51 30 81
2024 February 35 19 54
2024 January 41 24 65
2023 December 40 33 73
2023 November 48 42 90
2023 October 52 45 97
2023 September 43 46 89
2023 August 39 9 48
2023 July 60 15 75
2023 June 90 27 117
2023 May 79 19 98
2023 April 33 22 55
2023 March 56 29 85
2023 February 36 22 58
2023 January 41 21 62
2022 December 67 51 118
2022 November 63 37 100
2022 October 61 27 88
2022 September 63 52 115
2022 August 45 38 83
2022 July 45 38 83
2022 June 44 38 82
2022 May 38 35 73
2022 April 38 42 80
2022 March 34 39 73
2022 February 36 64 100
2022 January 44 44 88
2021 December 39 48 87
2021 November 41 43 84
2021 October 43 45 88
2021 September 31 34 65
2021 August 34 28 62
2021 July 26 39 65
2021 June 28 28 56
2021 May 38 36 74
2021 April 77 50 127
2021 March 3 3 6
2020 December 19 12 31
2020 November 15 16 31
2020 October 21 21 42
2020 September 13 22 35
2020 August 15 11 26
2020 July 22 22 44
2020 June 20 6 26
2020 May 26 13 39
2020 April 15 17 32
2020 March 21 11 32
2020 February 15 8 23
2020 January 17 15 32
2019 December 25 6 31
2019 November 26 7 33
2019 October 21 7 28
2019 September 29 11 40
2019 August 29 10 39
2019 July 18 14 32
2019 June 19 23 42
2019 May 24 29 53
2019 April 23 32 55
2019 March 29 18 47
2019 February 27 17 44
2019 January 29 33 62
2018 December 37 29 66
2018 November 32 22 54
2018 October 36 23 59
2018 September 23 38 61
2018 August 18 20 38
2018 July 27 15 42
2018 June 29 27 56
2018 May 26 34 60
2018 April 46 25 71
2018 March 29 12 41
2018 February 15 3 18
2018 January 30 6 36
2017 December 34 11 45
2017 November 19 7 26
2017 October 15 4 19
2017 September 14 12 26
2017 August 21 24 45
2017 July 21 28 49
2017 June 28 30 58
2017 May 39 33 72
2017 April 391 194 585
2017 March 15 13 28
2017 February 32 15 47
2017 January 25 11 36
2016 December 24 13 37
2016 November 35 10 45
2016 October 41 8 49
2016 September 27 14 41
2016 August 21 14 35
2016 July 20 6 26
2016 June 28 7 35
2016 May 37 17 54
2016 April 32 7 39
2016 March 23 11 34
2016 February 34 13 47
2016 January 34 10 44
2015 December 20 8 28
2015 November 22 10 32
2015 October 20 7 27
2015 September 32 13 45
2015 August 24 8 32
2015 July 25 4 29
2015 June 13 1 14
2015 May 19 6 25
2015 April 15 6 21
2015 March 32 4 36
2015 February 11 5 16
2015 January 11 5 16
2014 December 10 7 17
2014 November 16 9 25
2014 October 17 15 32
2014 September 8 30 38
2014 August 19 16 35
2014 July 15 14 29
Show all

Follow this link to access the full text of the article

Apunts Sports Medicine

Are you a health professional able to prescribe or dispense drugs?